IQGLF yields 33.33% · JNJ yields 2.13%● Live data
📍 IQGLF pulled ahead of the other in Year 1
Combined, IQGLF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IQGLF + JNJ for your $10,000?
IQGeo Group plc develops geospatial software to the telecoms and utility network industries in the United Kingdom, Europe, the United States, Canada, Japan, and internationally. The company provides IQGeo Platform, which designs and manages complex and constantly evolving network assets; IQGeo Network Manager that plans, designs, and supports network lifecycle through construction and maintenance operations; IQGeo Workflow Manager software, which helps to control telecom and utility construction and maintenance activities; IQGeo Inspection and Survey software that provides a flexible mobile interface for field inspection teams; and IQGeo Network Revenue Optimizer software, which automatically produces multiple telecom construction route options for connecting commercial or residential premises. It also offers IQGeo development environment to implement applications that work in any modern web browser and on any mobile device, online or offline; IQGeo Fiber Planning software, which automatically generates a cost-optimized next-generation fiber network plan and design; IQGeo in the cloud, a cloud hosting of critical system infrastructure; IQGeo GIS integrations for data integration from virtually any application and geospatial data source; and IQGeo professional services. The company was formerly known as Ubisense Group Plc and changed its name to IQGeo Group plc in January 2019. IQGeo Group plc was founded in 2002 and is headquartered in Cambridge, the United Kingdom.
Full IQGLF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.